醋酸阿比特龙联合泼尼松对转移性去势敏感性前列腺癌内脏转移患者四年随访的影响:LATITUDE 研究的事后探索性分析
LATITUDE 3 期研究事后分析,中位随访 51.8 个月,1199 例中 228 例(19%)基线有内脏转移。醋酸阿比特龙联合泼尼松(AA+P)较安慰剂改善内脏转移患者总生存(中位 55.4 vs 33.0 个月;HR=0.582;95%CI=0.406-0.835;P=0.0029)和影像学无进展生存(中位 30.7 vs 18.3 个月;HR=0.527;95%CI=0.366-0.759;P=0.0005)。
要点
- 内脏转移患者中 AA+P 较安慰剂改善总生存和影像学无进展生存。
- 肺转移患者 rPFS 获益(HR=0.50;95%CI=0.29-0.89;P=0.0157),肝转移患者未获益(HR=1.05;95%CI=0.53-2.09;P=0.8970)。
- 肝转移患者预后较差,其最佳治疗尚待明确。
核心结论
- AA+P 治疗改善转移性去势敏感性前列腺癌内脏转移男性的 rPFS 和 OS,尤其是肺转移患者。
- 肝转移患者预后较差,其最佳治疗尚待明确。
研究设计与样本
- LATITUDE 3 期研究的事后探索性分析。
- 新诊断 mCSPC 患者按 1:1 随机分配至 AA+P 联合 ADT 或安慰剂联合 ADT。
- 分析基线经 CT/MRI 确认有肝或肺内脏转移(伴或不伴其他软组织和骨转移)的患者,中位随访 51.8 个月。
- 共纳入 1199 例患者,228 例(19%)基线有内脏转移(AA+P 组和安慰剂组各 114 例)。
主要发现
- 内脏转移患者中,AA+P 组较安慰剂组 OS 改善:中位 55.4 vs 33.0 个月;HR=0.582;95%CI=0.406-0.835;P=0.0029。
- 内脏转移患者中,AA+P 组较安慰剂组 rPFS 改善:中位 30.7 vs 18.3 个月;HR=0.527;95%CI=0.366-0.759;P=0.0005。
- 内脏转移患者中 AA+P 的 OS 和 rPFS 获益与无内脏转移患者相当。
- 肺转移患者中 AA+P 较安慰剂 rPFS 改善:HR=0.50;95%CI=0.29-0.89;P=0.0157;肝转移患者中未观察到 rPFS 改善:HR=1.05;95%CI=0.53-2.09;P=0.8970。
- 肺转移患者中 AA+P 较安慰剂的 OS 改善(HR=0.60;95%CI=0.35-1.04;P=0.0678)大于肝转移患者(HR=0.82;95%CI=0.41-1.66;P=0.5814)。
关键数值与推荐
- 内脏转移患者中 53 例(23.2%;AA+P 组 29 例,安慰剂组 24 例)有肝转移,117 例(51.3%;AA+P 组 60 例,安慰剂组 57 例)有肺转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A post-hoc analysis of the phase-3 LATITUDE study assessed the impact of abiraterone acetate plus prednisone (AA+P) on overall survival (OS) and radiographic progression-free survival (rPFS) in men with metastatic castration-sensitive prostate cancer (mCSPC) and visceral metastases (VM). METHODS: Newly diagnosed mCSPC patients were randomized (1:1) to AA+P and androgen deprivation therapy (ADT) or placebo+ADT. Patients with VM in liver or lungs with or without other soft tissue and bone metastases (based on CT/MRI) at baseline were analyzed, after 51.8 months' median follow-up. Co-primary endpoints, OS and rPFS, were analyzed. RESULTS: Among 1199 patients enrolled, 228 (19%) had VM at baseline (114 each in AA+P and placebo groups), of which 53 (23.2%; AA+P = 29, Placebo = 24) had liver metastases and 117 (51.3%; AA+P = 60, Placebo = 57) had lung metastases. In patients with VM, treatment with AA+P versus placebo showed an improvement in OS (median 55.4 vs 33.0 months; HR = 0.582; 95%CI = 0.406-0.835;P = 0.0029) and rPFS (median 30.7 vs 18.3 months; HR = 0.527; 95%CI = 0.366-0.759;P = 0.0005), comparable to that of patients without VM. AA+P versus placebo in lung metastases patients was associated with greater improvement in OS (HR = 0.60; 95%CI = 0.35-1.04;P = 0.0678) than in liver metastases patients (HR = 0.82; 95%CI = 0.41-1.66;P = 0.5814). AA+P versus placebo showed improvement in rPFS in lung metastases patients (HR = 0.50; 95%CI = 0.29-0.89;P = 0.0157), but not in liver metastases patients (HR = 1.05; 95%CI = 0.53-2.09; P = 0.8970). CONCLUSION: AA+P treatment improved both rPFS and OS in men with mCSPC and visceral disease, especially those with lung metastases. Men with liver metastases had a poorer prognosis and their optimal treatment remains to be defined. REGISTRATION: ClinicalTrials.gov, number NCT01715285.
引用
- Baciarello G, Özgüroğlu M, Mundle S, et al. Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study. Eur J Cancer. 2021. PMID: 34953443. doi:10.1016/j.ejca.2021.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。